Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

Phase 2

Terminated

• Conditions: Diabetic Proliferative Retinopathy; Choroidal Neovascularization; Vascular Vein Oclussion

• Registration Number: NCT00417833
• Lead Sponsor: Asociación para Evitar la Ceguera en México

Brief Summary

Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG).

Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography and mf-ERG before and 1 month after treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-12
• Study Completion: 2006-07
• Study First Submitted: 2007-01-03
• Study First Submitted QC: 2007-01-03
• Study First Posted: 2007-01-04
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-31
• Last Update Posted: 2024-06-03

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Proliferative diabetic retinopathy, vascular vein oclussion, choroidal neovascularization
• Multifocal electroretinogram before intravitreal bevacizumab and at 1,3, and 6 months after treatment
• Completely studies

Exclusion Criteria

Complications

• Tractional Detachment
• Endophthalmitis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP